Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Method Article
* Wspomniani autorzy wnieśli do projektu równy wkład.
We report two cell synchronization protocols that provide a context for studying events related to specific phases of the cell cycle. We show that this approach is useful for analyzing the regulation of specific genes in an unperturbed cell cycle or upon exposure to agents affecting the cell cycle.
The gene expression program of the cell cycle represents a critical step for understanding cell cycle-dependent processes and their role in diseases such as cancer. Cell cycle-regulated gene expression analysis depends on cell synchronization into specific phases. Here we describe a method utilizing two complementary synchronization protocols that is commonly used for studying periodic variation of gene expression during the cell cycle. Both procedures are based on transiently blocking the cell cycle in one defined point. The synchronization protocol by hydroxyurea (HU) treatment leads to cellular arrest in late G1/early S phase, and release from HU-mediated arrest provides a cellular population uniformly progressing through S and G2/M. The synchronization protocol by thymidine and nocodazole (Thy-Noc) treatment blocks cells in early mitosis, and release from Thy-Noc mediated arrest provides a synchronized cellular population suitable for G1 phase and S phase-entry studies. Application of both procedures requires monitoring of the cell cycle distribution profiles, which is typically performed after propidium iodide (PI) staining of the cells and flow cytometry-mediated analysis of DNA content. We show that the combined use of two synchronization protocols is a robust approach to clearly determine the transcriptional profiles of genes that are differentially regulated in the cell cycle (i.e. E2F1 and E2F7), and consequently to have a better understanding of their role in cell cycle processes. Furthermore, we show that this approach is useful for the study of mechanisms underlying drug-based therapies (i.e. mitomycin C, an anticancer agent), because it allows to discriminate genes that are responsive to the genotoxic agent from those solely affected by cell cycle perturbations imposed by the agent.
Transition through all the phases of the cell cycle is coupled to a tightly regulated gene expression program. This coordinated "on and off" of gene transcription throughout the cell cycle is believed to be under the control of complex transcriptional regulatory systems, regulating not just the timing but also the levels of gene expression. Deregulation of key cell cycle components is known to contribute to the development of several diseases and is a well- established hallmark of tumorigenesis1,2. Genome-wide transcriptomic analyses carried out in yeast and mammalian cells have revealed that a large number of genes exhibit periodic gene expression patterns in the cell cycle, suggesting that transcriptional fluctuation during the cell cycle is a reflection of the temporal requirement of a given gene product in a precise phase3,4,5.
A major task in the study of cell cycle-regulated gene expression is the synchronization of cells into specific cell cycle phases. Cell synchronization helps to interpret association of a gene expression pattern to a particular cell cycle phase transition, and it has led to a better understanding of the regulation and function of numerous genes. Cell synchronization is also important for studying the mechanism of action of anticancer drugs, as chemotherapeutic agents are known to affect both gene expression as well as cell cycle kinetics6,7. Nevertheless, it is often difficult to determine whether gene expression differences resulting from treatment with these agents are a direct response to the treatment or are merely the consequence of changes in cell cycle profiles. To distinguish between these possibilities, gene expression should be analyzed in cells that have been synchronized prior to addition of the chemotherapeutic drug.
With the exception of some primary cells such as freshly isolated lymphoid cells -which constitute a homogeneous cell population synchronized in G08-, in vitro established cell lines grow asynchronously in culture. Under regular growth conditions, these asynchronously cycling cells are found in all phases of the cell cycle but, preferentially in G19. Therefore, this context does not provide an optimal scenario for functional or gene expression analyses in a specific cell cycle phase (e.g. G1, S etc.). Non-transformed immortalized cell lines (e.g. fibroblasts) can be synchronized with so-called physiological methods10. These methods are based on the retained primary cell features of non-transformed cells, such as cell-contact inhibition and growth factor dependency in order to continue cycling. Removal of serum in combination with contact inhibition renders non-transformed cells arrested at G0/G1. However, synchronized cell cycle entry and progression often requires subculture, which also involves artificial detachment of the cells and re-plating10. Most importantly, this method is not suitable for synchronization of transformed cell lines, the vast majority of established cell lines presently in use, characterized for lacking cell contact-mediated growth inhibition or response to growth factor withdrawal. Thus, it is clear that alternative methods are required for efficient cell synchronization in specific phases of the cell cycle. In general terms, the most frequently used synchronization methods are based on transient chemical or pharmacological inhibition of one defined point of the cell cycle, typically DNA synthesis or mitotic spindle formation. Inhibition of DNA synthesis synchronizes cells by arresting them in late G1 or early S phase. This can be achieved by the addition of compounds such as mimosine, an inhibitor of nucleotide biosynthesis11,12, aphidicolin, an inhibitor of DNA polymerases13,14, hydroxyurea, an inhibitor of ribonucleotide reductase15,16 or by excess amounts of thymidine17,18. On the other hand, inhibitors of microtubule polymerization, such as colchicine or nocodazole, are able to block mitotic spindle formation leading to cell synchronization at early M phase19,20,21.
In this work we describe a method involving two complementary synchronization protocols based on transient chemical inhibition for studying the expression of cell cycle-regulated genes at the mRNA level. This method is fundamental for defining the role of cell cycle genes in specific cell cycle processes. Furthermore, it provides a general frame for studying the impact of anticancer treatments in order to accurately detect drug responsive genes and to minimize misinterpretations derived from perturbations in cell cycle progression generated by these drugs.
1. Cellular Synchronization, Release and Monitoring of Cell Cycle Progression
2. Sample Collection and Processsing for Gene Expression Analysis
Schematic representation of Thy-Noc and HU-based protocols for cell synchronization.
Figure 1 summarizes the steps required for U2OS cell synchronization and subsequent sample collection in order to verify progression through the cell cycle and to perform gene expression analyses.
Phospho-H3 and PI staining are good evaluation parameters to select synchroniz...
Analysis of fine-tune regulated genes involved in transient and specific roles in the cell cycle requires a uniform cell population. Many researchers routinely use long-established tumor cell lines for these purposes, and a variety of methods have been developed to obtain synchronous (or partially synchronous) cell populations, with the aim to accumulate as many cells as possible in defined cell cycle phases. Moreover, strong efforts have been undertaken to improve and optimize well-established synchronization approaches...
The authors have nothing to disclose.
We thank members of the Zubiaga and the Altmeyer laboratories for helpful discussions and for technical support. This work was supported by grants from the Spanish Ministry (SAF2015-67562-R, MINECO/FEDER, UE), the Basque Government (IT634-13 and KK-2015/89), and the University of the Basque Country UPV/EHU (UFI11/20).
Name | Company | Catalog Number | Comments |
DMEM, high glucose, GutaMAX supplement | Thermo Fisher Scientific | 61965-059 | |
FBS, qualified, E.U.-approved, South America origin | Thermo Fisher Scientific | 10270-106 | |
Penicillin-Streptomycin (10,000 U/mL) | Thermo Fisher Scientific | 15140-122 | |
0.25% Trypsin-EDTA (1x), phenol red | Thermo Fisher Scientific | 25200-072 | |
Thymidine | SIGMA | T1895-5G | Freshly prepared. Slight warming might help dissolve thymidine. |
Nocodazole | SIGMA | M-1404 | Stock solution in DMSO stored at -20 ºC in small aliquots |
Hydroxyurea | SIGMA | H8627 | Freshly prepared |
Mitomycin C from Streptomyces caespitosus | SIGMA | M4287 | 1.5 mM stock solution in sterile H2O protected from light and stored at 4 ºC |
Dimethyl sulfoxide | SIGMA | D2650 | |
Propidium iodide | SIGMA | P4170 | Stock solution in sterile PBS at 5 mg/ml, stored at 4 º C protected from light. |
PBS pH 7.6 | Home made | ||
Ethanol | PANREAC | A3678,2500 | |
Chloroform | SIGMA | C2432 | |
Sodium Citrate | PANREAC | 131655 | |
Triton X-100 | SIGMA | T8787 | |
RNAse A | Thermo Fisher Scientific | EN0531 | |
TRIzol Reagent | LifeTechnologies | 15596018 | |
RNeasy Mini kit | QIAGEN | 74106 | |
High-Capacity cDNA Reverse Transcription Kit | Thermo Fisher Scientific | 4368814 | |
Anti-Cyclin E1 antibody | Cell Signaling | 4129 | 1:1000 dilution in 5% milk, o/n, 4 ºC |
Anti-Cyclin B1 antibody | Cell Signaling | 4135 | 1:1000 dilution in 5% milk, o/n, 4 ºC |
Anti-β-actin | SIGMA | A-5441 | 1:3000 dilution in 5 % milk, 1 hr, RT |
Anti-pH3 (Ser 10) antiboty | Millipore | 06-570 | Specified in the protocol |
Secondary anti-rabbit AlexaFluor 488 antibody | Invitrogen | R37116 | Specified in the protocol |
Secondary anti-mouse-HRP antibody | Santa Cruz Biotechnology | sc-3697 | 1:3000 dilution in 5 % milk, 1 hr, RT |
Forward E2F1 antibody (human) TGACATCACCAACGTCCTTGA | Biolegio | Designed by PrimerQuest tool (https://eu.idtdna.com/site) | |
Reverse E2F1 antibody (human) CTGTGCGAGGTCCTGGGTC | Biolegio | Designed by PrimerQuest tool (https://eu.idtdna.com/site) | |
Forward E2F7 antibody (human) GGAAAGGCAACAGCAAACTCT | Biolegio | Designed by PrimerQuest tool (https://eu.idtdna.com/site) | |
Reverse E2F7 antibody (human) TGGGAGAGCACCAAGAGTAGAAGA | Biolegio | Designed by PrimerQuest tool (https://eu.idtdna.com/site) | |
Forward p21Cip1 antibody (human) AGCAGAGGAAGACCATGTGGAC | Biolegio | Designed by PrimerQuest tool (https://eu.idtdna.com/site) | |
Reverse p21Cip1 antibody (human) TTTCGACCCTGAGAGTCTCCAG | Biolegio | Designed by PrimerQuest tool (https://eu.idtdna.com/site) | |
Forward TBP antibody (human) reference gene | Biolegio | Designed by PrimerQuest tool (https://eu.idtdna.com/site) | |
Reverse TBP antibody (human) | Biolegio | Designed by PrimerQuest tool (https://eu.idtdna.com/site) | |
Forward Oxa1L antibody (human) reference gene CACTTGCCAGAGATCCAGAAG | Biolegio | Designed by PrimerQuest tool (https://eu.idtdna.com/site) | |
Reverse Oxa1L antibody (human) CACAGGGAGAATGAGAGGTTTATAG | Biolegio | Designed by PrimerQuest tool (https://eu.idtdna.com/site) | |
Power SYBRGreen PCR Master Mix | Thermo Fisher Scientific | 4368702 | |
FACS Tubes | Sarstedt | 551578 | |
MicroAmp Optical 96-Well Reaction Plate | Thermo Fisher Scientific | N8010560 | |
Corning 100 mm TC-Treated Culture Dish | Corning | ||
Corning Costar cell culture plates 6 well | Corning | 3506 | |
Refrigerated Bench-Top Microcentrifuge | Eppendorf | 5415 R | |
Refrigerated Bench-Top Centrifuge Jouan CR3.12 | Jouan | 743205604 | |
NanoDrop Lite Spectrophotometer | Thermo Scientific | ND-LITE-PR | |
BD FACSCalibur Flow Cytometer | BD Bioscience | ||
QuantStudio 3 Real-Time PCR System | Thermo Fisher Scientific | A28567 |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone